Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant

Scott R. Solomon; Andrew St Martin; Mei Jie Zhang; Karen Ballen; Asad Bashey; Minoo Battiwalla; Lee Ann Baxter-Lowe; Claudio Brunstein; Saurabh Chhabra; Miguel Angel Diaz Perez; Ephraim J. Fuchs; Siddhartha Ganguly; Nancy Hardy; Peiman Hematti; Joseph McGuirk; Edward Peres; Olle Ringden; David Rizzieri; Rizwan Romee; Melhem Solh; David Szwajcer; Marjolein van der Poel; Edmund Waller; Basem M. William; Mary Eapen

doi:10.1016/j.bbmt.2020.06.029

Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant

Scott R. Solomon, Andrew St Martin, Mei Jie Zhang, Karen Ballen, Asad Bashey, Minoo Battiwalla, Lee Ann Baxter-Lowe, Claudio Brunstein, Saurabh Chhabra, Miguel Angel Diaz Perez, Ephraim J. Fuchs, Siddhartha Ganguly, Nancy Hardy, Peiman Hematti, Joseph McGuirk, Edward Peres, Olle Ringden, David Rizzieri, Rizwan Romee, Melhem SolhDavid Szwajcer, Marjolein van der Poel, Edmund Waller, Basem M. William, Mary Eapen

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Although hematopoietic cell transplantation from an HLA-matched unrelated donor is potentially curative for hematologic malignancies, survival is lower for African Americans compared with Caucasians. Because only approximately 20% of African Americans will have an HLA-matched unrelated donor, many of these patients undergo HLA-haploidentical relative or umbilical cord blood transplantation. In this study, we analyzed outcomes after HLA-haploidentical related donor (n = 249) and umbilical cord blood (n = 118) transplantations in African American patients with hematologic malignancy between 2008 and 2016. The predominant disease was acute myelogenous leukemia for recipients of both types of donor grafts. The incidences of grade II-IV and III-IV acute graft-versus-host disease were higher after umbilical cord blood transplantation compared with HLA-haploidentical relative transplantation (56% and 29%, respectively, versus 33% and 11%, respectively; P < .0001). The 2-year incidence of transplantation-related mortality adjusted for age and conditioning regimen intensity was higher after umbilical cord blood transplantation compared with HLA-haploidentical related donor transplantation (31% versus 18%; P = .008); however, there were no between-group differences in the 2-year adjusted incidence of relapse (30% versus 34%; P = .51), overall survival (54% versus 57%; P = .66), or disease-free survival (43% versus 47%; P = .46). Our findings show that the use of HLA-haploidentical and umbilical cord blood transplants expands the access to transplantation with comparable leukemia-free and overall survival for African Americans with hematologic malignancies.

Original language	English (US)
Pages (from-to)	1930-1936
Number of pages	7
Journal	Biology of Blood and Marrow Transplantation
Volume	26
Issue number	10
DOIs	https://doi.org/10.1016/j.bbmt.2020.06.029
State	Published - Oct 2020

Bibliographical note

Funding Information:
Financial disclosure: The Center for International Blood and Marrow Transplant Research is supported primarily by Public Health Service Grant/Cooperative Agreement 5U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases; Grant 5U10HL069294 from the NHLBI and NCI; Contract HHSH250201200016C with the Health Resources and Services Administration (HRSA); and Grants N00014-15-1-0848 and N00014-16-1-2020 from the Office of Naval Research. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, Department of the Navy, Department of Defense, HRSA, or any other agency of the US Government. Conflict of interest statement: There are no conflicts of interest to report. Financial disclosure: See Acknowledgments on page 1935.

Funding Information:
Financial disclosure: The Center for International Blood and Marrow Transplant Research is supported primarily by Public Health Service Grant/Cooperative Agreement 5U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases; Grant 5U10HL069294 from the NHLBI and NCI; Contract HHSH250201200016C with the Health Resources and Services Administration (HRSA); and Grants N00014-15-1-0848 and N00014-16-1-2020 from the Office of Naval Research. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, Department of the Navy, Department of Defense, HRSA, or any other agency of the US Government.

Publisher Copyright:
© 2020 American Society for Transplantation and Cellular Therapy

Keywords

African American
Alternative donor
Caucasian
leukemia
race
transplant-related mortality

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.bbmt.2020.06.029

OpenUrl availability

Full text

Cite this

Solomon, S. R., Martin, A. S., Zhang, M. J., Ballen, K., Bashey, A., Battiwalla, M., Baxter-Lowe, L. A., Brunstein, C., Chhabra, S., Perez, M. A. D., Fuchs, E. J., Ganguly, S., Hardy, N., Hematti, P., McGuirk, J., Peres, E., Ringden, O., Rizzieri, D., Romee, R., ... Eapen, M. (2020). Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant. Biology of Blood and Marrow Transplantation, 26(10), 1930-1936. https://doi.org/10.1016/j.bbmt.2020.06.029

Solomon, SR, Martin, AS, Zhang, MJ, Ballen, K, Bashey, A, Battiwalla, M, Baxter-Lowe, LA, Brunstein, C, Chhabra, S, Perez, MAD, Fuchs, EJ, Ganguly, S, Hardy, N, Hematti, P, McGuirk, J, Peres, E, Ringden, O, Rizzieri, D, Romee, R, Solh, M, Szwajcer, D, van der Poel, M, Waller, E, William, BM & Eapen, M 2020, 'Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant', Biology of Blood and Marrow Transplantation, vol. 26, no. 10, pp. 1930-1936. https://doi.org/10.1016/j.bbmt.2020.06.029

@article{da65011fa0244ea8891dd1ffa1384975,

title = "Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant",

abstract = "Although hematopoietic cell transplantation from an HLA-matched unrelated donor is potentially curative for hematologic malignancies, survival is lower for African Americans compared with Caucasians. Because only approximately 20% of African Americans will have an HLA-matched unrelated donor, many of these patients undergo HLA-haploidentical relative or umbilical cord blood transplantation. In this study, we analyzed outcomes after HLA-haploidentical related donor (n = 249) and umbilical cord blood (n = 118) transplantations in African American patients with hematologic malignancy between 2008 and 2016. The predominant disease was acute myelogenous leukemia for recipients of both types of donor grafts. The incidences of grade II-IV and III-IV acute graft-versus-host disease were higher after umbilical cord blood transplantation compared with HLA-haploidentical relative transplantation (56% and 29%, respectively, versus 33% and 11%, respectively; P < .0001). The 2-year incidence of transplantation-related mortality adjusted for age and conditioning regimen intensity was higher after umbilical cord blood transplantation compared with HLA-haploidentical related donor transplantation (31% versus 18%; P = .008); however, there were no between-group differences in the 2-year adjusted incidence of relapse (30% versus 34%; P = .51), overall survival (54% versus 57%; P = .66), or disease-free survival (43% versus 47%; P = .46). Our findings show that the use of HLA-haploidentical and umbilical cord blood transplants expands the access to transplantation with comparable leukemia-free and overall survival for African Americans with hematologic malignancies.",

keywords = "African American, Alternative donor, Caucasian, leukemia, race, transplant-related mortality",

author = "Solomon, {Scott R.} and Martin, {Andrew St} and Zhang, {Mei Jie} and Karen Ballen and Asad Bashey and Minoo Battiwalla and Baxter-Lowe, {Lee Ann} and Claudio Brunstein and Saurabh Chhabra and Perez, {Miguel Angel Diaz} and Fuchs, {Ephraim J.} and Siddhartha Ganguly and Nancy Hardy and Peiman Hematti and Joseph McGuirk and Edward Peres and Olle Ringden and David Rizzieri and Rizwan Romee and Melhem Solh and David Szwajcer and {van der Poel}, Marjolein and Edmund Waller and William, {Basem M.} and Mary Eapen",

note = "Funding Information: Financial disclosure: The Center for International Blood and Marrow Transplant Research is supported primarily by Public Health Service Grant/Cooperative Agreement 5U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases; Grant 5U10HL069294 from the NHLBI and NCI; Contract HHSH250201200016C with the Health Resources and Services Administration (HRSA); and Grants N00014-15-1-0848 and N00014-16-1-2020 from the Office of Naval Research. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, Department of the Navy, Department of Defense, HRSA, or any other agency of the US Government. Conflict of interest statement: There are no conflicts of interest to report. Financial disclosure: See Acknowledgments on page 1935. Funding Information: Financial disclosure: The Center for International Blood and Marrow Transplant Research is supported primarily by Public Health Service Grant/Cooperative Agreement 5U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases; Grant 5U10HL069294 from the NHLBI and NCI; Contract HHSH250201200016C with the Health Resources and Services Administration (HRSA); and Grants N00014-15-1-0848 and N00014-16-1-2020 from the Office of Naval Research. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, Department of the Navy, Department of Defense, HRSA, or any other agency of the US Government. Publisher Copyright: {\textcopyright} 2020 American Society for Transplantation and Cellular Therapy",

year = "2020",

month = oct,

doi = "10.1016/j.bbmt.2020.06.029",

language = "English (US)",

volume = "26",

pages = "1930--1936",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "10",

}

TY - JOUR

T1 - Optimal Donor for African Americans with Hematologic Malignancy

T2 - HLA-Haploidentical Relative or Umbilical Cord Blood Transplant

AU - Solomon, Scott R.

AU - Martin, Andrew St

AU - Zhang, Mei Jie

AU - Ballen, Karen

AU - Bashey, Asad

AU - Battiwalla, Minoo

AU - Baxter-Lowe, Lee Ann

AU - Brunstein, Claudio

AU - Chhabra, Saurabh

AU - Perez, Miguel Angel Diaz

AU - Fuchs, Ephraim J.

AU - Ganguly, Siddhartha

AU - Hardy, Nancy

AU - Hematti, Peiman

AU - McGuirk, Joseph

AU - Peres, Edward

AU - Ringden, Olle

AU - Rizzieri, David

AU - Romee, Rizwan

AU - Solh, Melhem

AU - Szwajcer, David

AU - van der Poel, Marjolein

AU - Waller, Edmund

AU - William, Basem M.

AU - Eapen, Mary

N1 - Funding Information: Financial disclosure: The Center for International Blood and Marrow Transplant Research is supported primarily by Public Health Service Grant/Cooperative Agreement 5U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases; Grant 5U10HL069294 from the NHLBI and NCI; Contract HHSH250201200016C with the Health Resources and Services Administration (HRSA); and Grants N00014-15-1-0848 and N00014-16-1-2020 from the Office of Naval Research. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, Department of the Navy, Department of Defense, HRSA, or any other agency of the US Government. Conflict of interest statement: There are no conflicts of interest to report. Financial disclosure: See Acknowledgments on page 1935. Funding Information: Financial disclosure: The Center for International Blood and Marrow Transplant Research is supported primarily by Public Health Service Grant/Cooperative Agreement 5U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases; Grant 5U10HL069294 from the NHLBI and NCI; Contract HHSH250201200016C with the Health Resources and Services Administration (HRSA); and Grants N00014-15-1-0848 and N00014-16-1-2020 from the Office of Naval Research. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, Department of the Navy, Department of Defense, HRSA, or any other agency of the US Government. Publisher Copyright: © 2020 American Society for Transplantation and Cellular Therapy

PY - 2020/10

Y1 - 2020/10

N2 - Although hematopoietic cell transplantation from an HLA-matched unrelated donor is potentially curative for hematologic malignancies, survival is lower for African Americans compared with Caucasians. Because only approximately 20% of African Americans will have an HLA-matched unrelated donor, many of these patients undergo HLA-haploidentical relative or umbilical cord blood transplantation. In this study, we analyzed outcomes after HLA-haploidentical related donor (n = 249) and umbilical cord blood (n = 118) transplantations in African American patients with hematologic malignancy between 2008 and 2016. The predominant disease was acute myelogenous leukemia for recipients of both types of donor grafts. The incidences of grade II-IV and III-IV acute graft-versus-host disease were higher after umbilical cord blood transplantation compared with HLA-haploidentical relative transplantation (56% and 29%, respectively, versus 33% and 11%, respectively; P < .0001). The 2-year incidence of transplantation-related mortality adjusted for age and conditioning regimen intensity was higher after umbilical cord blood transplantation compared with HLA-haploidentical related donor transplantation (31% versus 18%; P = .008); however, there were no between-group differences in the 2-year adjusted incidence of relapse (30% versus 34%; P = .51), overall survival (54% versus 57%; P = .66), or disease-free survival (43% versus 47%; P = .46). Our findings show that the use of HLA-haploidentical and umbilical cord blood transplants expands the access to transplantation with comparable leukemia-free and overall survival for African Americans with hematologic malignancies.

AB - Although hematopoietic cell transplantation from an HLA-matched unrelated donor is potentially curative for hematologic malignancies, survival is lower for African Americans compared with Caucasians. Because only approximately 20% of African Americans will have an HLA-matched unrelated donor, many of these patients undergo HLA-haploidentical relative or umbilical cord blood transplantation. In this study, we analyzed outcomes after HLA-haploidentical related donor (n = 249) and umbilical cord blood (n = 118) transplantations in African American patients with hematologic malignancy between 2008 and 2016. The predominant disease was acute myelogenous leukemia for recipients of both types of donor grafts. The incidences of grade II-IV and III-IV acute graft-versus-host disease were higher after umbilical cord blood transplantation compared with HLA-haploidentical relative transplantation (56% and 29%, respectively, versus 33% and 11%, respectively; P < .0001). The 2-year incidence of transplantation-related mortality adjusted for age and conditioning regimen intensity was higher after umbilical cord blood transplantation compared with HLA-haploidentical related donor transplantation (31% versus 18%; P = .008); however, there were no between-group differences in the 2-year adjusted incidence of relapse (30% versus 34%; P = .51), overall survival (54% versus 57%; P = .66), or disease-free survival (43% versus 47%; P = .46). Our findings show that the use of HLA-haploidentical and umbilical cord blood transplants expands the access to transplantation with comparable leukemia-free and overall survival for African Americans with hematologic malignancies.

KW - African American

KW - Alternative donor

KW - Caucasian

KW - leukemia

KW - race

KW - transplant-related mortality

UR - http://www.scopus.com/inward/record.url?scp=85089075393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089075393&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2020.06.029

DO - 10.1016/j.bbmt.2020.06.029

M3 - Article

C2 - 32649981

AN - SCOPUS:85089075393

SN - 1083-8791

VL - 26

SP - 1930

EP - 1936

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 10

ER -

Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this